688189 南新制药
交易中 12-16 14:26:34
资讯
新帖
简况
南新制药拟变更2025年度审计机构为华兴会计师事务所
中金财经 · 12-11
南新制药拟变更2025年度审计机构为华兴会计师事务所
南新制药股份回购比例达1%
证券日报 · 12-10
南新制药股份回购比例达1%
兴业证券:26Q2预计家电外销景气优于内销 推荐石头科技(688189.SH)等
智通财经 · 12-10
兴业证券:26Q2预计家电外销景气优于内销 推荐石头科技(688189.SH)等
南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,12月1日股价下跌2.01%
证券之星 · 12-01
南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,12月1日股价下跌2.01%
南新制药前三季度亏损扩大,公司面临被监管立案等多重困境
中科财经 · 11-14
南新制药前三季度亏损扩大,公司面临被监管立案等多重困境
每周股票复盘:南新制药(688189)累计回购357,179股
证券之星 · 11-09
每周股票复盘:南新制药(688189)累计回购357,179股
每周股票复盘:南新制药(688189)股东户数增49.13%,营收下滑净利亏损
证券之星 · 11-02
每周股票复盘:南新制药(688189)股东户数增49.13%,营收下滑净利亏损
南新制药(688189)9月30日股东户数1.41万户,较上期增加49.13%
证券之星 · 10-31
南新制药(688189)9月30日股东户数1.41万户,较上期增加49.13%
每周股票复盘:南新制药(688189)提前归还1亿元募集资金
证券之星 · 10-26
每周股票复盘:南新制药(688189)提前归还1亿元募集资金
南新制药(688189)披露提前归还临时用于补充流动资金的募集资金,10月21日股价上涨0.73%
证券之星 · 10-21
南新制药(688189)披露提前归还临时用于补充流动资金的募集资金,10月21日股价上涨0.73%
股市必读:南新制药(688189)10月10日收盘跌11.98%,主力净流入68.68万元
证券之星 · 10-13
股市必读:南新制药(688189)10月10日收盘跌11.98%,主力净流入68.68万元
10月10日南新制药跌11.98%,大成景恒混合A基金重仓该股
证券之星 · 10-10
10月10日南新制药跌11.98%,大成景恒混合A基金重仓该股
南新制药(688189)披露股票交易严重异常波动公告,10月09日股价下跌19.96%
中金财经 · 10-10
南新制药(688189)披露股票交易严重异常波动公告,10月09日股价下跌19.96%
股市必读:南新制药因涉嫌违反证券法律法规等违规行为被证监会立案调查
证券之星 · 10-09
股市必读:南新制药因涉嫌违反证券法律法规等违规行为被证监会立案调查
南新制药(688189.SH)终止筹划重大资产重组事项
智通财经 · 09-30
南新制药(688189.SH)终止筹划重大资产重组事项
南新制药最新公告:涉嫌年报信息披露违法违规 被证监会立案调查
证券之星 · 09-30
南新制药最新公告:涉嫌年报信息披露违法违规 被证监会立案调查
每周股票复盘:南新制药(688189)拟取消监事会并修订章程
证券之星 · 09-28
每周股票复盘:南新制药(688189)拟取消监事会并修订章程
刚刚,5家公司发布利空公告
证券之星 · 09-24
刚刚,5家公司发布利空公告
南新制药股东计划在10月27日至2026年1月26日期间减持不超过3%股份
美股速递 · 09-24
南新制药股东计划在10月27日至2026年1月26日期间减持不超过3%股份
南新制药最新公告:股东广州乾元拟减持不超过3.00%公司股份
证券之星 · 09-24
南新制药最新公告:股东广州乾元拟减持不超过3.00%公司股份
加载更多
公司概况
公司名称:
湖南南新制药股份有限公司
所属行业:
医药制造业
上市日期:
2020-03-26
主营业务:
湖南南新制药股份有限公司的主营业务是流行性感冒等抗病毒、传染病防治药品,以及恶性肿瘤、心脑血管疾病、糖尿病等其他重大疾病治疗药品研发、生产与销售。公司的主要产品是帕拉米韦氯化钠注射液、磷酸奥司他韦干混悬剂、辛伐他汀分散片、阿托伐他汀钙片、贝那普利氢氯噻嗪片、头孢呋辛酯分散片、头孢克洛胶囊、头孢克洛干混悬剂、乳酸环丙沙星氯化钠注射液、复方布洛芬片、布洛芬混悬滴剂、布洛芬混悬液、盐酸非索非那定口服混悬液。
发行价格:
34.94
{"stockData":{"symbol":"688189","market":"SH","secType":"STK","nameCN":"南新制药","latestPrice":8.06,"timestamp":1765866394000,"preClose":8.21,"halted":0,"volume":3763635,"delay":0,"changeRate":-0.0183,"floatShares":274000000,"shares":274000000,"eps":-1.3423,"marketStatus":"交易中","change":-0.15,"latestTime":"12-16 14:26:34","open":8.25,"high":8.25,"low":8.01,"amount":30459300,"amplitude":0.0292,"askPrice":8.06,"askSize":110,"bidPrice":8.05,"bidSize":411,"shortable":0,"etf":0,"ttmEps":-1.3423,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765868400000},"marketStatusCode":2,"adr":0,"adjPreClose":8.21,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765848600000,1765855800000],[1765861200000,1765868400000]],"highLimit":9.03,"lowLimit":7.39,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":274400000,"isCdr":false,"pbRate":2.6,"roa":"--","roe":"--","epsLYR":-1.3007,"committee":0.518863,"marketValue":2212000000,"turnoverRate":0.0137,"status":1,"floatMarketCap":2212000000},"requestUrl":"/m/hq/s/688189","defaultTab":"news","newsList":[{"id":"2590056923","title":"南新制药拟变更2025年度审计机构为华兴会计师事务所","url":"https://stock-news.laohu8.com/highlight/detail?id=2590056923","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590056923?lang=zh_cn&edition=full","pubTime":"2025-12-11 12:46","pubTimestamp":1765428372,"startTime":"0","endTime":"0","summary":"中访网数据 湖南南新制药股份有限公司于2025年12月10日召开董事会,审议通过变更2025年度审计机构的议案。公司拟聘任华兴会计师事务所(特殊普通合伙)担任2025年度财务报告及内部控制审计机构,以替代原审计机构大华会计师事务所(特殊普通合伙)。此次变更主要基于公司业务发展及审计服务需求,旨在确保年度审计工作的顺利开展。华兴会计师事务所2024年度审计业务收入为35,599.98万元,具备为上市公司提供审计服务的专业能力。本次审计费用总额为213万元,较上年度增加6万元。公司已就变更事宜与前后任会计师事务所进行沟通,双方均无异议。该议案尚需提交公司股东大会审议批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251211/31858805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2590358298","title":"南新制药股份回购比例达1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590358298","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590358298?lang=zh_cn&edition=full","pubTime":"2025-12-10 20:11","pubTimestamp":1765368660,"startTime":"0","endTime":"0","summary":"本报讯 12月10日晚间,湖南南新制药(维权)股份有限公司公告,截至2025年12月10日,公司通过集中竞价交易方式累计回购股份约274.4万股,占公司总股本的1.00%。 未来,南新制药将继续严格遵循相关法律法规,根据市场情况择机推进后续回购工作,同时持续聚焦主业发展,提升核心竞争力与盈利能力,以优异的经营业绩回报广大投资者、赋能员工成长、助力行业进步。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-10/doc-inhaiqhy9779468.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-10/doc-inhaiqhy9779468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2590743383","title":"兴业证券:26Q2预计家电外销景气优于内销 推荐石头科技(688189.SH)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2590743383","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590743383?lang=zh_cn&edition=full","pubTime":"2025-12-10 10:34","pubTimestamp":1765334084,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,兴业证券发布研报称,展望2026年,考虑国补退坡及高基数,预计家电内销有所承压,趋势上前低后高;26Q2起外销进入较低基数区间,叠加关税影响逐步缓和、美联储降息预期催化、欧美需求修复与新兴市场高增兑现,预计外销景气优于内销。中系品牌内外市场发力,有望持续抢占市场并提升结构。展望2026年,该行认为国补政策及宏观经济仍是左右小家电内需的关键。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兴业证券:26Q2预计家电外销景气优于内销 推荐石头科技(688189.SH)等","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688189","BK0224","BK0028","BK0188","BK0276","BK0183","LU2328871848.SGD","601377","688169","BK0214","BK0239","BK0012","LU1969619763.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2588725995","title":"南新制药(688189)披露以集中竞价交易方式回购公司股份的进展公告,12月1日股价下跌2.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588725995","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588725995?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:52","pubTimestamp":1764582777,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘,南新制药报收于9.28元,较前一交易日下跌2.01%,最新总市值为25.46亿元。公司近日发布公告称,湖南南新制药股份有限公司于2025年4月28日召开董事会,审议通过以集中竞价交易方式回购公司股份的方案,回购资金总额预计为1,000万元至2,000万元,用于员工持股计划或股权激励,回购价格不超过9.53元/股,回购期限为12个月。2025年11月单月回购600,841股,支付资金5,301,612.05元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100023274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2583701145","title":"南新制药前三季度亏损扩大,公司面临被监管立案等多重困境","url":"https://stock-news.laohu8.com/highlight/detail?id=2583701145","media":"中科财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583701145?lang=zh_cn&edition=full","pubTime":"2025-11-14 18:24","pubTimestamp":1763115840,"startTime":"0","endTime":"0","summary":"11月10日,南新制药召开2025年第三季度业绩说明会。值得注意的是,在本次业绩说明会上,南新制药并未就近一个月公司涉嫌信披违规被监管立案和公司重组事宜进行说明。同时,南新制药4.8亿元重大资产重组项目,在筹划仅一个多月后便宣告终止。业绩亏损扩大 重组终止三季报显示,南新制药第三季度营业收入为2130.81万元,环比增长0.41%。2025年9月30日晚,南新制药发布公告称,因涉嫌年报信息披露违法违规,被中国证监会立案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxkpat1502658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2582861781","title":"每周股票复盘:南新制药(688189)累计回购357,179股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861781","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582861781?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:23","pubTimestamp":1762633389,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,南新制药报收于9.06元,较上周的9.17元下跌1.2%。本周,南新制药11月3日盘中最高价报9.76元。本周关注点公司公告汇总:截至2025年10月31日,南新制药累计回购股份357,179股,占总股本的0.13%。截至2025年10月31日,公司累计回购股份357,179股,占公司总股本274,400,000股的0.13%,累计已回购金额为2,696,235.78元,回购价格区间为7.02元/股至7.97元/股。2025年10月单月回购股份91,663股,占总股本0.03%,支付资金总额728,841.86元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2580477633","title":"每周股票复盘:南新制药(688189)股东户数增49.13%,营收下滑净利亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2580477633","media":"证券之星","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580477633?lang=zh_cn&edition=full","pubTime":"2025-11-02 07:28","pubTimestamp":1762039696,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,南新制药报收于9.17元,较上周的8.42元上涨8.91%。本周,南新制药10月31日盘中最高价报9.35元。南新制药当前最新总市值25.16亿元,在化学制药板块市值排名142/151,在两市A股市值排名4860/5163。股本股东变化股东户数变动截至2025年9月30日,公司股东户数为1.41万户,较6月30日增加4650户,增幅49.13%。南新制药2020年首发募集资金净额113,528.23万元,截至2025年9月30日累计使用87,879.57万元,专户余额15,962.14万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200001601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189"],"gpt_icon":0},{"id":"2579451357","title":"南新制药(688189)9月30日股东户数1.41万户,较上期增加49.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579451357","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579451357?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:33","pubTimestamp":1761903226,"startTime":"0","endTime":"0","summary":"证券之星消息,近日南新制药披露,截至2025年9月30日公司股东户数为1.41万户,较6月30日增加4650.0户,增幅为49.13%。在化学制药行业个股中,南新制药股东户数低于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.44万户。从股价来看,2025年6月30日至2025年9月30日,南新制药区间涨幅为52.82%,在此期间股东户数增加4650.0户,增幅为49.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100036853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2578502679","title":"每周股票复盘:南新制药(688189)提前归还1亿元募集资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2578502679","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578502679?lang=zh_cn&edition=full","pubTime":"2025-10-26 03:06","pubTimestamp":1761419174,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘,南新制药报收于8.42元,较上周的7.95元上涨5.91%。本周,南新制药10月22日盘中最高价报8.96元。南新制药当前最新总市值23.1亿元,在化学制药板块市值排名146/150,在两市A股市值排名4978/5160。本周关注点公司公告汇总:南新制药已提前全额归还临时补充流动资金的募集资金1亿元。公司已于到期前将上述资金全部提前归还至募集资金专用账户,并通知了保荐机构及保荐代表人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2577790338","title":"南新制药(688189)披露提前归还临时用于补充流动资金的募集资金,10月21日股价上涨0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577790338","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577790338?lang=zh_cn&edition=full","pubTime":"2025-10-21 22:20","pubTimestamp":1761056428,"startTime":"0","endTime":"0","summary":"截至2025年10月21日收盘,南新制药报收于8.28元,较前一交易日上涨0.73%,最新总市值为22.72亿元。该股当日开盘8.24元,最高8.29元,最低8.12元,成交额达8347.51万元,换手率为3.7%。公司近日发布公告称,截至2025年10月21日,已累计归还临时补充流动资金的闲置募集资金人民币10,000.00万元。2025年10月21日,公司已将上述资金全部提前归还至募集资金专用账户,并将归还情况通知了保荐机构及保荐代表人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102100037013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2575844899","title":"股市必读:南新制药(688189)10月10日收盘跌11.98%,主力净流入68.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575844899","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575844899?lang=zh_cn&edition=full","pubTime":"2025-10-13 05:38","pubTimestamp":1760305097,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘,南新制药报收于8.01元,下跌11.98%,换手率13.58%,成交量37.27万手,成交额2.97亿元。当日关注点来自交易信息汇总:南新制药股价连续3日下跌,近5个交易日中2日跌幅超5%,10月10日收盘跌11.98%至8.01元,主力资金前10日累计净流出1.41亿元。公司公告汇总湖南南新制药股份有限公司股票连续30个交易日内收盘价格跌幅偏离值累计达到70%,构成严重异常波动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300002058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2574123446","title":"10月10日南新制药跌11.98%,大成景恒混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2574123446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574123446?lang=zh_cn&edition=full","pubTime":"2025-10-10 16:23","pubTimestamp":1760084607,"startTime":"0","endTime":"0","summary":"证券之星消息,10月10日南新制药跌11.98%创60日新低,收盘报8.01元,换手率13.58%,成交量37.27万手,成交额2.97亿元。重仓南新制药的公募基金请见下表:根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为大成基金的大成景恒混合A。大成景恒混合A目前规模为3.97亿元,最新净值3.5272,较上一交易日上涨0.54%,近一年上涨58.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000024753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2574154561","title":"南新制药(688189)披露股票交易严重异常波动公告,10月09日股价下跌19.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574154561","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574154561?lang=zh_cn&edition=full","pubTime":"2025-10-10 08:06","pubTimestamp":1760054793,"startTime":"0","endTime":"0","summary":"公司近日发布股票交易严重异常波动公告,称其股票在连续30个交易日内收盘价格跌幅偏离值累计达到70%,构成严重异常波动。公告显示,公司近日收到中国证监会《立案告知书》,因涉嫌年报信息披露违法违规被立案。除上述事项外,公司及控股股东不存在其他应披露而未披露的重大事项。在股票异常波动期间,公司董监高及控股股东无买卖公司股票的行为。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251010/31694576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2574971669","title":"股市必读:南新制药因涉嫌违反证券法律法规等违规行为被证监会立案调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2574971669","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574971669?lang=zh_cn&edition=full","pubTime":"2025-10-09 02:51","pubTimestamp":1759949473,"startTime":"0","endTime":"0","summary":"截至2025年9月30日收盘,南新制药报收于11.37元,下跌0.61%,换手率1.76%,成交量4.83万手,成交额5508.22万元。当日关注点来自交易信息汇总:9月30日主力资金净流出946.72万元,占总成交额17.19%。来自违规处罚提醒:10月1日南新制药因涉嫌信息披露违规被证监会立案调查。违规处罚提醒监管公告10月1日南新制药公开信息显示,湖南南新制药股份有限公司因涉嫌违反证券法律法规,信息披露违规被中国证券监督管理委员会立案调查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900000820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239","161027"],"gpt_icon":0},{"id":"2571341763","title":"南新制药(688189.SH)终止筹划重大资产重组事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2571341763","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571341763?lang=zh_cn&edition=full","pubTime":"2025-09-30 19:24","pubTimestamp":1759231489,"startTime":"0","endTime":"0","summary":"智通财经APP讯,南新制药(688189.SH)发布公告,此前,公司与西藏未来生物医药股份有限公司、许昌未来制药有限责任公司和合肥市未来药物开发有限公司(以下合称“未来医药”或“标的公司”)签署了《收购意向协议》,公司拟以现金方式收购未来医药持有的标的资产组。《收购意向协议》签署后,公司积极组织交易各方推进本次交易。公司与交易对方就本次交易的可行性、交易方案的核心条款等进行了多次论证和磋商,但最终未能就本次交易的核心条款达成一致意见。为切实维护公司及全体股东利益,经公司审慎研究,并与交易对方友好协商,交易各方一致同意终止筹划本次交易,并于近日签署了《收购终止协议》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1351426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2571346693","title":"南新制药最新公告:涉嫌年报信息披露违法违规 被证监会立案调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2571346693","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571346693?lang=zh_cn&edition=full","pubTime":"2025-09-30 18:21","pubTimestamp":1759227663,"startTime":"0","endTime":"0","summary":"南新制药(688189.SH)公告称,公司近日收到中国证监会出具的《立案告知书》,因公司涉嫌年报信息披露违法违规,中国证监会决定对公司立案。立案调查期间,公司将积极配合中国证监会的调查工作,并严格按照相关法律法规及监管要求及时履行信息披露义务。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025093000030897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688189"],"gpt_icon":0},{"id":"2570899816","title":"每周股票复盘:南新制药(688189)拟取消监事会并修订章程","url":"https://stock-news.laohu8.com/highlight/detail?id=2570899816","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570899816?lang=zh_cn&edition=full","pubTime":"2025-09-28 01:54","pubTimestamp":1758995655,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘,南新制药报收于11.23元,较上周的12.24元下跌8.25%。会议审议《关于取消监事会并修订<公司章程>的议案》。现场会议于当日10:00在广州市黄埔区开源大道196号广州南新制药有限公司313会议室举行。湖南南新制药股份有限公司拟取消监事会,由董事会审计委员会行使监事会职权,相应废止《监事会议事规则》,并对《公司章程》进行修订。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092800000377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2569010757","title":"刚刚,5家公司发布利空公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2569010757","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569010757?lang=zh_cn&edition=full","pubTime":"2025-09-24 20:52","pubTimestamp":1758718350,"startTime":"0","endTime":"0","summary":"9月24日,多家上市公司发布利空公告。1,国芯科技:四名股东拟合计减持公司不超4.5%股份9月24日,国芯科技公告称,因基金退出需要,西藏津盛泰达创业投资有限公司拟减持公司股份850万股,占公司总股本的2.53%。此次减持不会导致公司控制权变更,也不会对公司治理结构及持续经营产生影响。公司董事会秘书王尚博拟减持不超过公司总股本0.01%的股份,减持期间为自公告披露之日起15个交易日后的三个月内。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025092400037614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688262","688776","BK0239","BK0226","002719","300542","BK0077","BK0214","688189","BK0231"],"gpt_icon":0},{"id":"1197099105","title":"南新制药股东计划在10月27日至2026年1月26日期间减持不超过3%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1197099105","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197099105?lang=zh_cn&edition=full","pubTime":"2025-09-24 20:47","pubTimestamp":1758718041,"startTime":"0","endTime":"0","summary":"南新制药发布公告称,公司股东计划在2024年10月27日至2026年1月26日期间减持所持有的公司股份,减持比例不超过公司总股本的3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688189","BK0239"],"gpt_icon":0},{"id":"2569951706","title":"南新制药最新公告:股东广州乾元拟减持不超过3.00%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2569951706","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569951706?lang=zh_cn&edition=full","pubTime":"2025-09-24 19:50","pubTimestamp":1758714656,"startTime":"0","endTime":"0","summary":"南新制药(688189.SH)公告称,股东广州乾元投资咨询合伙企业(有限合伙)因资金需求,计划通过集中竞价交易和大宗交易方式减持其所持有的公司股份,合计减持股份数量不超过8,232,000股,不超过公司总股本的3.00%。减持期间为2025年10月27日至2026年1月26日。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092400035769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688189","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765866457590,"stockEarnings":[{"period":"1week","weight":-0.0692},{"period":"1month","weight":-0.1798},{"period":"3month","weight":-0.3685},{"period":"6month","weight":0.0947},{"period":"1year","weight":0.0566},{"period":"ytd","weight":0.2554}],"compareEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":-0.0307},{"period":"3month","weight":0.0016},{"period":"6month","weight":0.1414},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.154}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南南新制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14114人(较上一季度增加49.13%)","perCapita":"19441股","listingDate":"2020-03-26","address":"湖南省长沙市浏阳市经济技术开发区康里路1号","registeredCapital":"27440万元","survey":" 湖南南新制药股份有限公司的主营业务是流行性感冒等抗病毒、传染病防治药品,以及恶性肿瘤、心脑血管疾病、糖尿病等其他重大疾病治疗药品研发、生产与销售。公司的主要产品是帕拉米韦氯化钠注射液、磷酸奥司他韦干混悬剂、辛伐他汀分散片、阿托伐他汀钙片、贝那普利氢氯噻嗪片、头孢呋辛酯分散片、头孢克洛胶囊、头孢克洛干混悬剂、乳酸环丙沙星氯化钠注射液、复方布洛芬片、布洛芬混悬滴剂、布洛芬混悬液、盐酸非索非那定口服混悬液。","listedPrice":34.94},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"南新制药(688189)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供南新制药(688189)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"南新制药,688189,南新制药股票,南新制药股票老虎,南新制药股票老虎国际,南新制药行情,南新制药股票行情,南新制药股价,南新制药股市,南新制药股票价格,南新制药股票交易,南新制药股票购买,南新制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"南新制药(688189)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供南新制药(688189)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}